Dr. Verjee is the founder of Versante. He is a biostatistician with over 30 years of pharmaceutical and biotechnology industry experience. His passion is in coming up with solutions to problems that seem intractable. He is focused on assisting companies with NDA and BLA submissions, streamlining data-related operations and optimizing clinical development plans and study designs.


He has been associated with the development, submissions and / or approvals of several block-buster drugs. These include AmbienŽ, BetaseronŽ, BusparŽ, DepakaneŽ, FludareŽ, EnkaidŽ, KerloneŽ and most recently ProvengeŽ.


He currently serves on several Scientific Advisory boards and Data Safety Monitoring committees. Prior to forming Versante International, LLC., Dr. Verjee was Senior Director and corporate Head of Biometrics USA at Berlex Laboratories, Inc., a subsidiary of Schering A.G. He also served as Director, Biostatistics and Research Data Systems for Lorex Pharmaceuticals, a joint venture of Synthelabo and G.D. Searle, and as Associate Director, Biostatistics and Site Director of Bristol-Myers Company. Dr. Verjee started his career with Abbott Laboratories working in both preclinical and clinical statistics. He also served as a Senior Statistician at Ethicon, a medical device company and a division of Johnson and Johnson. He has also taught statistics at leading universities in the USA and Brazil.


Dr. Verjee earned his Ph.D. in Statistics from the University of Chicago and his B.Sc. in Mathematics from University College, Nairobi, Kenya.
Statistical Analysis and Reporting
Clinical Plan Development
Protocol Development and Study Design
Therapeutic Expertise Consultation
Data Management
Electronic Data Capture (EDC)
CDISC Conversion
Copyright © 2009 Versante International, LLC. All rights reserved. Legal Notices | Privacy Policy